Lack of tolerance development with long-term administration of PEGylated cholecystokinin

Isabelle Verbaeys (First Author), Fabián León-Tamariz, Johan Buyse, Eddy Decuypere, Hans Pottel, Marnix Cokelaere (Last Author)

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Cholecystokinin (CCK) is a short acting satiating peptide hormone produced in the proximal small intestine. Daily CCK injection in rats initially inhibits food intake, but after several days, food intake is no longer affected, suggesting development of tolerance. Previously, we covalently coupled CCK to a 10 kDa polyethylene glycol (mPEG-OH) and showed that this conjugate, PEG-CCK9, produced a significantly longer anorectic effect than unmodified CCK9. The present study examined whether tolerance to the anorectic effect develops during long-term administration of PEG-CCK9. For 14 consecutive days, male Wistar rats (n = 12) received a daily i.p injection of 8 μg kg-1 of PEG-CCK9 and a control group received a daily control injection of mPEG-OH. Body weight and food intake were monitored daily during the experiment. Effects on the pancreas were investigated. On each day, injection of PEG-CCK9 induced an anorectic effect lasting 3-6 h, but failed to significantly reduce daily total food intake compared to controls. The body weight gain of the PEG-CCK9-treated animals was not different from controls. The PEG-CCK9-treated group had a significantly higher pancreas weight, mainly due to hyperplasia. In conclusion, PEG-CCK9 continued to have a daily suppressive effect on food intake when administered for 14 consecutive days, showing there was no development of tolerance.

Original languageEnglish
Pages (from-to)699-704
Number of pages6
JournalPeptides
Volume30
Issue number4
DOIs
StatePublished - Apr 2009
Externally publishedYes

Keywords

  • Cholecystokinin
  • Long-term administration
  • Pancreas proliferation
  • PEGylated Cholecystokinin
  • Satiety
  • Tolerance

Fingerprint

Dive into the research topics of 'Lack of tolerance development with long-term administration of PEGylated cholecystokinin'. Together they form a unique fingerprint.

Cite this